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  The measurement of human prostatic acid phosphatase （PAP） was studied using PAP RIA KIT
which was first established in Japan by Eiken lmmunochernical Laboratory．
  The immunological activity of ．PAP was’ stable for 24 hours at room temperature and had no
cross－reactivity with erythrocytes．
  In the’ clinical phase， PAP was measured in the serum obtained from 37 patients with benign
prostatic hypertrophy， 47 patients with treated and untreated prostatic cancer， 43 patients with other
urological diseases and 3’1 vplunteers of healthy adult men． ’From this result， it was concluded that
’the nortnal range of PAP was less than’3．19 ng／ml．
  ’ln the grouP of untreated prostatic cancer， the positivity of PAP by tadioimmun’oassay was 780／．
in stage III and 1000／， in stage IV． ln both stages， it was highgr tban that of ehzym4tic assay． False
positive by radioimmunoassay was 5 to ．100／，， and false negative 140／，．
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Fig． 2． Stability of immunological PAP activity at room temperature．
               Table 1．
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Fig． 3． Disttibution of PAP concentration in
     serum of healthy men （n！31）， of
    patients with BPH （n＝37）， of patients
    with treated prostatic cancer’・（n’±＝’．3．1）
    of patients with untreated prostatic
     cancer （n＝14），．and of pati．engs’with
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Fig；・4．Correlation between values of serum
    PAP ． concentration measyred by ．rad－
    oimrn． u／ QaS＄aY and enZYmatic assay in
    patients of treated prostatic cancer．
Serum PAP level By radioimmunoassay
Patients No． of cases 一PAP｛il｝Ranqe （ rnean±SD｝
A｝ Normal males
B） Benign p rostatic
 hypertrophy
C｝ Prostatic qancer
 ｛Foiiow up cases． ）・
D） Prostatic cancer
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Fig，6。 Effect of estrogen therapy and cεしstration
       ．for 1》AP concCnt．ra’tiQII in pat量cnts with
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Fig．5． Cotrelation between values of serum
       PAP concentration measured・ by rad－
       ioimmunoassay and enzymatic assay in
       patients ofuptreated prostatic cancer．
Table 3． Correlation between PAP concentration and
         untreated prost’atic cancer．
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Table 4． Correlation between PAP concentration and clinical stage in untreated
         ．prostatlc ． cqncer．







｛ No． of cases ）
Metastasis ｛t）．












































































 （N ＝ 43）
67％
10％   130ノ・  10％
57．’●
1go’。 16。’。           8◎’。
55。’。
21％           、             15％                    6％                                3％
7go’。




          噂1．09     陶2，14    陶3，19    働4．24      4・25隔
              PAP concentration （ nglmt ＞
Fig． 7． Percentage of healthy men， patients with BPH， patients with treated
    and untreated prostatic cancer， and patients with other diseases in
    each PAP conecntration by radioimmunoassay．
il．ge． ＃． ． b｝． h． i；RI．A． 一PSAP























 本KIT以外のPAP RIA KITとしては， Mal－














II， III， IVの4 Stageに分け， PAP濃度が3．19 ngt
ml以下を正常域とした場合のPAP陽性率をRIA
法および酵素法において比較検討した．RIA法にお






（Stage IV）などの， high stageの前立腺癌において，
酵素法に比較してすぐれた診断方法であると思われる．
これに対して前立腺癌が前立瞭被膜内に限局している

















Percent positivity of serum PAP assay in prostatic cancer







100 （   5
63 ｛5
  3’，8
60 ｛  5
＃ A positive was defined as the serum contained an amount of PAP
 greater than 3．2ng per ml in radioimmunoassay or 1．O unit per ml
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